tiprankstipranks

CANbridge Pharmaceuticals Postpones Board Meeting for Annual Results Approval

Story Highlights
CANbridge Pharmaceuticals Postpones Board Meeting for Annual Results Approval

CANbridge Pharmaceuticals Inc. ( (HK:1228) ) has provided an update.

CANbridge Pharmaceuticals Inc. has announced the postponement of its board meeting originally scheduled for March 28, 2025, to March 31, 2025. The delay aims to ensure maximum attendance of directors for the approval of the company’s 2024 annual results, reflecting the company’s commitment to thorough governance and stakeholder transparency.

More about CANbridge Pharmaceuticals Inc.

CANbridge Pharmaceuticals Inc. is a biopharmaceutical company incorporated in the Cayman Islands, focusing on developing and commercializing innovative therapies for rare diseases and targeted cancers.

YTD Price Performance: 12.31%

Average Trading Volume: 1,123,339

Technical Sentiment Signal: Buy

Current Market Cap: HK$62.03M

For detailed information about 1228 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App